

Telitacept

Cat. No.:	HY-P99568
CAS No.:	2136630-26-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Telitacept (RC18) is a fully human TACI-Fc fusion protein. Telitacept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacept can be used in research of B-cell autoimmune disease ^[1] .									
IC₅₀ & Target	(BLyS)/APRIL ^[1]									
In Vivo	<p>Telitacept (15 and 7.5mpk, i.p.) improves mouse experimental autoimmune encephalomyelitis (EAE) clinical symptoms in MOG₃₅₋₅₅ induced EAE model mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>MOG₃₅₋₅₅ peptide-induced EAE mice model (6- to 8-week-old, female)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>15mpk and 7.5mpk</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td> <p>Reduced the severity of tail paralyzes and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927).</p> <p>Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.</p> </td> </tr> </table>		Animal Model:	MOG ₃₅₋₅₅ peptide-induced EAE mice model (6- to 8-week-old, female) ^[2]	Dosage:	15mpk and 7.5mpk	Administration:	i.p.	Result:	<p>Reduced the severity of tail paralyzes and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927).</p> <p>Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.</p>
Animal Model:	MOG ₃₅₋₅₅ peptide-induced EAE mice model (6- to 8-week-old, female) ^[2]									
Dosage:	15mpk and 7.5mpk									
Administration:	i.p.									
Result:	<p>Reduced the severity of tail paralyzes and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927).</p> <p>Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.</p>									

REFERENCES

- [1]. Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. *Eur J Pharm Sci.* 2021 Apr 1;159:105704.
- [2]. Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. *Journal of Immunological Sciences.* March 31, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA